Pharmosa Biopharm Inc. (TPEX:6875)

Pharmosa Biopharm Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	716.52	749.44	974.06	672.51	461.46	414.54
Short-Term Investments	500	869	-	-	-	-
Cash & Short-Term Investments	1,217	1,618	974.06	672.51	461.46	414.54
Cash Growth	-24.57%	66.16%	44.84%	45.73%	11.32%	9672.18%
Accounts Receivable	-	4.65	-	-	-	-
Other Receivables	14.44	6.69	1.47	0.29	0.31	0.15
Receivables	14.44	11.34	1.47	0.29	0.31	0.15
Inventory	36.6	24.74	21.91	-	-	-
Prepaid Expenses	43.89	27.22	12.67	11.65	14.18	8.69
Other Current Assets	2.14	-	-	-	0.02	4
Total Current Assets	1,314	1,682	1,010	684.45	475.96	427.37
Property, Plant & Equipment	406.71	315.06	180.61	30.12	33.44	40.86
Long-Term Investments	73.04	73.26	71.22	65.69	61.6	60.91
Other Intangible Assets	1.09	0.66	0.09	0.15	0.18	-
Other Long-Term Assets	63.08	92.88	71.62	18.95	15.19	14.13
Total Assets	1,858	2,164	1,334	799.37	586.37	543.27
Accounts Payable	0.4	0.68	0.59	-	-	-
Accrued Expenses	37.29	61.51	33.24	12.28	11.66	10.43
Short-Term Debt	-	-	-	-	-	61
Current Portion of Long-Term Debt	-	-	1.26	3.52	8.43	18.81
Current Portion of Leases	18.45	17.98	24.69	7.19	6.8	6.43
Current Unearned Revenue	23.45	6.89	-	-	-	-
Other Current Liabilities	15.18	29.07	17.8	4.77	6.19	2.58
Total Current Liabilities	94.78	116.13	77.58	27.77	33.07	99.25
Long-Term Debt	-	-	1.19	2.45	5.96	14.83
Long-Term Leases	85.72	99.62	117.23	8.04	15.9	23.36
Long-Term Unearned Revenue	4.82	4.82	-	-	-	-
Other Long-Term Liabilities	5.23	5.1	-	-	-	-
Total Liabilities	190.54	225.66	195.99	38.25	54.93	137.44
Common Stock	645.43	645.43	586.02	554.67	489.24	402.5
Additional Paid-In Capital	1,282	1,439	531.34	1,180	-	454.19
Retained Earnings	-260	-146.37	20.28	-973.44	-706.94	-450.46
Comprehensive Income & Other	0	0.02	0.01	0.01	749.13	-0.41
Shareholders' Equity	1,667	1,938	1,138	761.12	531.44	405.83
Total Liabilities & Equity	1,858	2,164	1,334	799.37	586.37	543.27
Total Debt	104.17	117.6	144.37	21.19	37.09	124.43
Net Cash (Debt)	1,112	1,501	829.69	651.32	424.37	290.1
Net Cash Growth	-25.39%	80.89%	27.39%	53.48%	46.28%	-
Net Cash Per Share	8.62	11.87	7.32	6.61	5.00	6.09
Filing Date Shares Outstanding	129.09	129.09	117.2	110.93	97.85	49.99
Total Common Shares Outstanding	129.09	129.09	117.2	110.93	97.85	49.99
Working Capital	1,219	1,566	932.53	656.68	442.89	328.12
Book Value Per Share	12.91	15.01	9.71	6.86	5.43	8.12
Tangible Book Value	1,666	1,937	1,138	760.97	531.25	405.83
Tangible Book Value Per Share	12.91	15.01	9.71	6.86	5.43	8.12
Machinery	110.86	68.34	27.11	26.37	17.05	19.59
Construction In Progress	211.87	134.42	-	-	-	-
Leasehold Improvements	30.19	28.85	35.61	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.